Tags

Type your tag names separated by a space and hit enter

A decade of experience with rotavirus vaccination in the United States - vaccine uptake, effectiveness, and impact.
Expert Rev Vaccines 2018; 17(7):593-606ER

Abstract

INTRODUCTION

Prior to 2006, nearly every U.S. child was infected with rotavirus by 5 years of age, and rotavirus was the leading cause of severe childhood gastroenteritis. In February 2006 and June 2008, the Advisory Committee on Immunization Practices recommended a live attenuated pentavalent rotavirus vaccine (RV5) and a monovalent rotavirus vaccine (RV1), respectively, for routine vaccination of infants in the United States.

AREAS COVERED

We reviewed U.S. data on coverage, vaccine effectiveness (VE), and vaccine impact from 2006 to 2017. National rotavirus vaccine coverage estimates increased since vaccine introduction but plateaued at 71-75% in 2013-2015, a level 15-20% lower than that of other routine childhood vaccines. Pooled VE of full series RV5 and RV1 against rotavirus-associated hospitalizations and emergency department visits were 84% (95% CI: 80-87%) and 83% (95% CI: 72-89%), respectively. Vaccine introduction resulted in a median decline in rotavirus-associated hospitalizations and emergency department visits of 80% and 57%, respectively, along with indirect protection of unvaccinated age groups and a decrease in health-care costs. A biennial pattern in rotavirus detection emerged post-vaccine implementation.

EXPERT COMMENTARY

The increasing use of rotavirus vaccines has substantially diminished the burden and changed the epidemiology of rotavirus disease in U.S. children; efforts to increase rotavirus vaccine coverage should continue.

Authors+Show Affiliations

a Epidemic Intelligence Service , Centers for Disease Control and Prevention , Atlanta , GA , USA. b Viral Gastroenteritis Branch, Division of Viral Diseases , Centers for Disease Control and Prevention , Atlanta , GA , USA.b Viral Gastroenteritis Branch, Division of Viral Diseases , Centers for Disease Control and Prevention , Atlanta , GA , USA.b Viral Gastroenteritis Branch, Division of Viral Diseases , Centers for Disease Control and Prevention , Atlanta , GA , USA.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

29909693

Citation

Pindyck, Talia, et al. "A Decade of Experience With Rotavirus Vaccination in the United States - Vaccine Uptake, Effectiveness, and Impact." Expert Review of Vaccines, vol. 17, no. 7, 2018, pp. 593-606.
Pindyck T, Tate JE, Parashar UD. A decade of experience with rotavirus vaccination in the United States - vaccine uptake, effectiveness, and impact. Expert Rev Vaccines. 2018;17(7):593-606.
Pindyck, T., Tate, J. E., & Parashar, U. D. (2018). A decade of experience with rotavirus vaccination in the United States - vaccine uptake, effectiveness, and impact. Expert Review of Vaccines, 17(7), pp. 593-606. doi:10.1080/14760584.2018.1489724.
Pindyck T, Tate JE, Parashar UD. A Decade of Experience With Rotavirus Vaccination in the United States - Vaccine Uptake, Effectiveness, and Impact. Expert Rev Vaccines. 2018;17(7):593-606. PubMed PMID: 29909693.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A decade of experience with rotavirus vaccination in the United States - vaccine uptake, effectiveness, and impact. AU - Pindyck,Talia, AU - Tate,Jacqueline E, AU - Parashar,Umesh D, Y1 - 2018/07/02/ PY - 2018/6/19/pubmed PY - 2019/1/4/medline PY - 2018/6/19/entrez KW - RotaTeq KW - Rotarix KW - Rotavirus KW - gastroenteritis KW - vaccination program KW - vaccine SP - 593 EP - 606 JF - Expert review of vaccines JO - Expert Rev Vaccines VL - 17 IS - 7 N2 - INTRODUCTION: Prior to 2006, nearly every U.S. child was infected with rotavirus by 5 years of age, and rotavirus was the leading cause of severe childhood gastroenteritis. In February 2006 and June 2008, the Advisory Committee on Immunization Practices recommended a live attenuated pentavalent rotavirus vaccine (RV5) and a monovalent rotavirus vaccine (RV1), respectively, for routine vaccination of infants in the United States. AREAS COVERED: We reviewed U.S. data on coverage, vaccine effectiveness (VE), and vaccine impact from 2006 to 2017. National rotavirus vaccine coverage estimates increased since vaccine introduction but plateaued at 71-75% in 2013-2015, a level 15-20% lower than that of other routine childhood vaccines. Pooled VE of full series RV5 and RV1 against rotavirus-associated hospitalizations and emergency department visits were 84% (95% CI: 80-87%) and 83% (95% CI: 72-89%), respectively. Vaccine introduction resulted in a median decline in rotavirus-associated hospitalizations and emergency department visits of 80% and 57%, respectively, along with indirect protection of unvaccinated age groups and a decrease in health-care costs. A biennial pattern in rotavirus detection emerged post-vaccine implementation. EXPERT COMMENTARY: The increasing use of rotavirus vaccines has substantially diminished the burden and changed the epidemiology of rotavirus disease in U.S. children; efforts to increase rotavirus vaccine coverage should continue. SN - 1744-8395 UR - https://www.unboundmedicine.com/medline/citation/29909693/A_decade_of_experience_with_rotavirus_vaccination_in_the_United_States___vaccine_uptake_effectiveness_and_impact_ L2 - http://www.tandfonline.com/doi/full/10.1080/14760584.2018.1489724 DB - PRIME DP - Unbound Medicine ER -